Base de dados : HANSEN
Pesquisa : DAPSONA/FARMACOL [Descritor de assunto]
Referências encontradas : 25 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 25 HANSEN  
              next record last record
seleciona
para imprimir
Texto Completo-en
Id:26781
Autor:Ji, Baohong.
Título:Does dapsone resistance really matter in the MDT era?.
Fonte:Int. J. Lepr;69(1):54-55, Mar., 2001. .
Descritores:Dapsona/imunol
Dapsona/farmacol
Dapsona/uso terap
Hanseníase/quimioter
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2001/pdf/v69n1/v69n1cor09.pdf - en.
Localização:BR191.1


  2 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-pt
Id:25883
Autor:Hadler, W. A; Ziti, L. M.
Título:Algumas observações sôbre o modo de ação do 4- 4'-diaminodifenilsulfona na lepra murina / Some Observations on the mode of action of 4 - 4'-diaminodiphenyl in murine leprosy
Fonte:Rev. bras. Leprol;24(1-2):56-68, jan-jun.- 1956. ^btab, ^bgraf.
Resumo:Some aspects of the sulfone action on the murine leprosy were studied in rats, which were inoculated by the intraperitoneal route with 5, 5 mg of M. lepraemurium and then treated with 4- 4'-diamino-diphenylsulfone (DDS). The treatment was made by the oral route, 0,2 or 0,3 per cent of DDS being added to the food. The animals were divided into the following lots: Lot 1A - 20 rats treated with 0,2 per cent of DDS. Lote 1B - 20 untreated control rats. 2A - 20 rats inoculated with bacilli obtained from an animal of the lot 1A, preliminarily treated with DDS during 180 days; these animals then received 0,2 per cent of DDS mixed with the food. Lot 2B - 20 untreated control rats, which were inoculated with bacilli recovered from a rat of the lot 1B. Lot 3A - 20 rats inoculated with bacilli recovered from an animal of the lot 2A, which had previously been treated with DDS for 180 days; afterwards these animals received 0,2 per cent of DDS in the food. Lot 3B - 20 rats inoculated with the same material as the lot 3A, but afterwards treated with 0,3 per cent of DDS given with the food. Lot 3C - 20 rats inoculated with same material as the lot 3A, and kept as untreated controls. Lot 3D - 20 rats inoculated with bacilli obtained from an animal of the lot 2B; these rats were afterwards treated with DDS (0,3 per cent in the food). Lot 3E - 20 untreated control rats, inoculated with the same material as the lot 3D. The results of the treatment were based upon the survical time and the intensity of the lesions. The statistical analysis of the medium survical time in these lots of animals shows, that they constitute 3 groups. The lots which integrate these groups do not present significant difference when compared together. A first group comprises the control animals (lots 1B, 2B and 3E); a second group includes the animals inoculated with bacilli recovered from the control rats and then treated with DDS (lots 1A and 3D) and the animals inoculated with bacilli obtained from previo^ien.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Hanseníase/fisiopatol
Hanseníase/reabil
Hanseníase/terap
Dapsona/sint quim
Dapsona/farmacol
Dapsona/uso terap
Limites:Humanos
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1956/PDF/v24n1-2/v24n1-2a06.pdf - pt.
Localização:BR191.1


  3 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25373
Autor:Gokhale, N. R; Sule, R. R; Gharpure, M. B
Título:Dapsone syndrome
..-
Fonte:s.l; s.n; 1992. 3p p. .
Descritores:DAPSONA/admin
DAPSONA/ef adv
DAPSONA/farmacol
DAPSONA/farmacocin
DAPSONA/tox
DAPSONA/uso terap
HANSENIASE/terap
 QUIMIOTERAPIA COMBINADA
Limites:HUMANO
Localização:BR191.1; 01165/s


  4 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:24713
Autor:Sampaio, Sebastiao AP; Rivitti, Evandro A.
Título:Hanseníase / Leprosy
Fonte:In: Sampaio, Sebastiao AP; Rivitti, Evandro A.Dermatologia. Sao Paulo, Artes Medicas, 2007. p.625-651ilus, graf.
Descritores:HANSENIASE/imunol
HANSENIASE/microbiol
HANSENIASE/prev
HANSENIASE/fisiopatol
HANSENIASE/reabil
HANSENIASE/terap
MYCOBACTERIUM LEPRAE/citol
MYCOBACTERIUM LEPRAE/genet
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/fisiol
ANTIGENO DE MITSUDA/quim
ANTIGENO DE MITSUDA/fisiol
RIFAMPINA/farmacol
 RIFAMPINA/uso terap
 DAPSONA/farmacol
 DAPSONA/uso terap
 CLOFAZIMINA/farmacol
 CLOFAZIMINA/uso terap
Limites:ESTUDO COMPARATIVO
HUMANO
Localização:Br191.1; WR100, S47d


  5 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:23914
Autor:Organizaçao Mundial da Saude*.
Título:Lepra: aprender com os exitos
Leprosy to learn with the successes-
Fonte:s.l; OMS; 2001. 36 p. ilus, graf.
Descritores:HANSENIASE/diag
HANSENIASE/reabil
HANSENIASE/terap
SAUDE PÚBLICA/educ
SAUDE PÚBLICA/instrum
SAUDE PÚBLICA/tend
CURA
DAPSONA/anal
DAPSONA/farmacol
DAPSONA/uso terap
ORGANIZACAO MUNDIAL DA SAUDE/org
Limites:RELATO DE CASO
HUMANO
Localização:BR191.1; WC335.19, O14L


  6 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:22965
Autor:Burchfield, H. P; Storrs, E. E; Walsh, G. P; Green, L. L
Título:Metabolic disposition of dapsona by armadillos
?-
Fonte:s.l; s.n; s.d. 19p p. .
Descritores:TATUS/metab
MYCOBACTERIUM LEPRAE/patogen
DAPSONA/farmacol
Limites:ANIMAL
Localização:BR191.1; 01112/d.a


  7 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18041
Autor:Shepard, Charles C; Levy, Louis; Fasal, Paul
Título:Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae
..-
Fonte:s.l; s.n; nov. 1974. 5 p. tab, graf.
Resumo:The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients lesions. In a trial of rifampin in a dosage of 600mg daily, the bacterial viability feel to undectable levels in the first specimen taken after the start of theraphy (at 3-4 days in 4 patients, 7-8 days in 9, and 4 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3-5 days in all 14 patients).(AU).
Descritores:FATORES DE TEMPO
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE/ef drogas
DAPSONA/admin
DAPSONA/farmacol
ENSAIOS CLINICOS
RELACAO DOSE-RESPOSTA A DROGA
BIOPSIA
RIFAMPINA/admin
RIFAMPINA/farmacol
Limites:HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01966/s


  8 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17968
Autor:Dubey, G. K; Joglekar, V. K; Hardas, U. D; Chaubey, B. S
Título:A study of cell mediated immunity in leprosy
..-
Fonte:s.l; s.n; apr. 1981. 7 p. tab, graf.
Resumo:This paper presents a review of 123 cases of leprosy of different clinical types as regards to their status of cellular immunity. These 123 cases included 41 fresh cases, 18 cases of reaction and 64 cases of leprosy taking antileprosy treatment. Out of 41 untreated cases only 11 turned up for follow up and their lymphoblastic transformation was repeated 4 to 6 months after initiating the treatment. It was observed that cell mediated immunity as expressed in terms of percentage of blast cells is definitely depressed in leprosy, most in LL and least in TT. There is a definite increase in the percentage of blast cells after taking antileprosy treatment. The rise in percentage of blast cells and hence cellular immunity is relatively more in patients treated with Lamprene as compared to those treated with DDS. Reactions also have impact over immunity in leprosy. Thus, most of the patients with ENL show higher values for blast percentage as compared to those with lepra reaction. It appears that serial lymphocyte cultures if done in all cases of leprosy undergoing treatment will help in assessment of individual progress.(AU).
Descritores:IMUNIDADE CELULAR/ef drogas
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
HANSENIASE/imunol
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
DAPSONA/farmacol
DAPSONA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 00771/s


  9 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17940
Autor:Belda, Walter; Margarido, Leontina C; Marlet, José Maria; Martinez, Ednir A. L. W; Kliemann, Teresa J. A. E; Lombardi, Clóvis; Junior Belda, W
Título:Estudo comparativo das médias móveis, dos índices baciloscópico e morfológico, em pacientes de hanseníase virchoviana tratados pela rifampicina e pela diamino-difenil-sulfona
Comparative study of the variable averages and bacilloscopic and morphologic indexes in Virchowian Hansen patients treated with rifampicin and diaminediphenylsulfone-
Fonte:s.l; s.n; jun. 1979. 10 p. tab, graf.
Resumo:São apresentados resultados clínicos e baciloscópicos obtidos, em estudo comparativo, na experimentação terapêutica da ação da rifampicina e diamino-difenil-sulfona na hanseníase virchoviana. Respectivamente 23 e 24 pacientes, relativamente homogeneizados, foram observados por um período mínimo de 12 meses e máximo de 24. É ressaltada a superioridade da ação da rifampicina, nos primeiros meses, em termos clínicos, e de redução do número de bacilos viáveis. É recomendado, pelo menos como etapa inicial do tratamento, o emprego da rifampicina da terapêutica da hanseníase virchoviana.(AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/microbiol
HANSENIASE/patol
DAPSONA/farmacol
DAPSONA/uso terap
MYCOBACTERIUM LEPRAE/ef drogas
RIFAMPINA/farmacol
RIFAMPINA/uso terap
Limites:ESTUDO COMPARATIVO
HUMANO
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 00588/s


  10 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17923
Autor:Rasbridge, Marian R; Scott, G. L
Título:The haemolytic action of dapsone: the effect on red-cell glycolysis
..-
Fonte:s.l; s.n; feb. 1973. 13 p. tab, graf.
Resumo:Some aspects of red-cell matabolism were studied in blood samples taken from patients on long-term dapsone therapy. Glucose consumption by the Embden-Meyerhof pathway (EMP) was not abnormal and adenosine-triphosphate (ATP) levels lay within the normal range and were well maintained during incubation. Hexose monophosphate patchway (HMP) activity was increased above that which would be expected from the age of the red-cell population. Red-cell reduced glutathione (GSH) levels tended to be lower than normal, proportional to the dose od dapsone and GSH levels were unstable on incubation. Red-cell fractionation studies showed that the older cell fraction had lower GSH levels and more Heinz bodies but proportionally greater HMP activity than the younger cell fraction. It is suggested that the low GSH levels are probably due to the binding of GSH to sulphydryl groups in haemoglobin and possibly the red-cell membrane. The increased HMP activity in the older cells many, in part, be a compensatory mechanism.(AU).
Descritores:ADENOSINA TRIFOSFATO/sangue
DAPSONA/ef adv
DAPSONA/farmacol
DERMATITE HERPETIFORME/quimioter
ENVELHECIMENTO ERITROCITICO
ERITROCITOS/enzimol
ERITROCITOS/metab
GLUCOSEFOSFATO DESIDROGENASE/sangue
GLUTATIONA/sangue
CORPOS DE HEINZ
Meio Eletrônico: - .
Localização:BR191.1; 01856/s


  11 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17920
Autor:Prabhakaran, K; Harris, E. B; Kirchheimer, W. F
Título:A possible method for improving the efficacy of dapsone
..-
Fonte:s.l; s.n; December 15, 1980. 2 p. tab.
Resumo:The antileprosy drug dapsone is unable to penetrate intact Mycobacterium leprae in vitro, as determined by its effect on o-diphenoloxidase in the bacilli. When combined with the peptide polylysine, the sulfone drug passes through the bacterial cell membranes, and penetrates the enzyme protein, resulting in a 100% inhibition of its activity.
Descritores:CATECOL OXIDASE/antag
PERMEABILIDADE DA MEMBRANA CELULAR/ef drogas
COMBINACAO DE MEDICAMENTOS
CONCENTRACAO DE IONS DE HIDROGÊNIO
MYCOBACTERIUM LEPRAE/enzimol
PEPTIDIOS/uso terap
DAPSONA/admin
DAPSONA/farmacol
POLILISINA/farmacol
POLILISINA/uso terap
Meio Eletrônico: - .
Localização:BR191.1; 00684/s


  12 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17893
Autor:Anderson, R; Gatner, E. M. S; van Rensburg, C. E; Grabow, G; Imkamp, F. M. G. H; Kok, S. K; van Rensburg, A. J
Título:In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy
..-
Fonte:s.l; s.n; apr. 1981. 9 p. tab, graf.
Resumo:The effects of dapsone on polymorphonuclear leukocyte functions and lymphocyte mitogen-induced transformation were assessed in vitro and in vivo in normal individuals and in newly diagnosed untreated patients with lepromatous leprosy. The effects of dapsone on the cell-free generation of superoxide by the xanthine: xanthine oxidase system and iodination of bovine serum albumin by horseradish peroxidase were also investigated. In normal individuals dapsone mediated stimulation of polymorphonuclear leukocyte migration in vitro and vivo. Dapsone had no effect on postphagocytic hexose monophosphate shunt activity in vivo. Similar effects were found in patients with lepromatous leprosy. Dapsone also decreased the inhibitory activity of serum from patients with lepromatous leprosy on normal polymorphonuclear leukocyte migration in vitro. Progressive loss of serum-mediated inhibition of migration was observed after ingestion of dapsone by the patients. Further experiments showed that stimulation of polymorphonuclear leukocyte motility was related to inhibition of lymphocyte transformation at high concentrations in vitro, but had slight stimulatory activity on phytohemagglutinin-induced transformation in controls and patients in vivo.(AU).
Descritores:PEROXIDASE/metab
SUPEROXIDOS/metab
HANSENIASE/sangue
PEROXIDO DE HIDROGÊNIO/metab
TRANSFORMACAO LINFOCITICA/ef drogas
LINFOCITOS/ef drogas
NEUTROFILOS/ef drogas
FAGOCITOSE/ef drogas
MOVIMENTO CELULAR/ef drogas
DAPSONA/farmacol
Limites:HUMANO
IN VITRO
Meio Eletrônico: - .
Localização:BR191.1; 00756/s


  13 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17886
Autor:Taylor, P. M
Título:The clinical diagnosis of dapsone resistant leprosy
..-
Fonte:s.l; s.n; jan. 1982. 6 p. ilus.
Resumo:For the early recognition of dapsone resistance, it is essential to regularly examine patients at risk for suspicious new lesions, backed by regular clinical treatment records including smear results. The earlier the recognition and starting on alternative treatment, the better is the response. However, it is not advisable to change treatment without attempting at least clinical confirmation, and endorsing the chart so that the problem is not missed on subsequent occasions.(AU).
Descritores:RESISTÊNCIA MICROBIANA A DROGAS
PELE/patol
MYCOBACTERIUM LEPRAE/ef drogas
DAPSONA/admin
DAPSONA/farmacol
DAPSONA/uso terap
HANSENIASE/quimioter
HANSENIASE/patol
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 00913/s


  14 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16341
Autor:Williams, Diana L; Pittman, Tana L; Gillis, Thomas P; Matsuoka, Masanori; Kashiwabara, Yoshiko
Título:Simultaneous detection of mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis
..-
Fonte:s.l; s.n; Jun. 2001. 6 p. ilus, tab.
Descritores:SEQUENCIA DE BASES
DNA BACTERIANO
DNA BACTERIANO
DAPSONA
RESISTENCIA MICROBIANA A DROGAS
LEPROSTATICOS
HANSENIASE
DADOS DE SEQUENCIA MOLECULAR
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
SENSIBILIDADE E ESPECIFICIDADE
ANALISE DE SEQUENCIA DE DNA
Análise Heteroduplex/*MT
Localização:BR191.1; 08678/s; BR191.1; 08430/s


  15 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16324
Autor:Dhople, Arvind M
Título:In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against mycobacterium leprae
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Descritores:ADMINISTRAÇAO ORAL
TATUS
DAPSONA
DAPSONA
SINERGISMO DE DROGAS
ANTAGONISTAS DO ACIDO FOLICO
ANTAGONISTAS DO ACIDO FOLICO
LEPROSTATICOS
LEPROSTATICOS
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
TRIMETOPRIM
TRIMETOPRIM
TRIMETOPRIM
Limites:ANIMAL
Localização:BR191.1; 08715/s


  16 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15707
Autor:Dhople, Arvind M
Título:In vivo activity of epiroprim, a dihydrofolate reductase inhitor, singly and in combination with dapsone, against Mycobacterium leprae
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Descritores:HANSENIASE
LEPROSTATICOS
LEPROSTATICOS
ADMINISTRAÇAO ORAL
DAPSONA
DAPSONA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
TRIMETOPRIM
TRIMETOPRIM
TRIMETOPRIM
Localização:BR191.1; 08453/s


  17 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15655
Autor:Williams, Diana L; Pittman, Tana L; Gillis, Thomas P; Matsuoka, Masanori; Kashiwabara, Yoshiko
Título:Simultaneous detection of mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis
..-
Fonte:s.l; s.n; 2001. 6 p. tab, graf.
Descritores:SEQUENCIA DE BASES
DNA BACTERIANO
DNA BACTERIANO
DAPSONA
RESISTENCIA MICROBIANA A DROGAS
LEPROSTATICOS
HANSENIASE
DADOS DE SEQUENCIA MOLECULAR
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
SENSIBILIDADE E ESPECIFICIDADE
ANALISE DE SEQUENCIA DE DNA
ANALISE HETERODUPLEX/*MT
Localização:BR191.1; 08430/s


  18 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14988
Autor:Kai, Masanori; Matsuoka, Masanori; Nakata, Noboru; Maeda, Shinji; Gidoh, Masaichi; Maeda, Yumi; Hashimoto, Ken; Kobayashi, Kazuo; Kashiwabara, Yoshiko
Título:Diaminodiphenylsulfone resistance of mycobacterium leprae due to mutations in the dihydropteroate synthase gene
..-
Fonte:s.l; s.n; 1999. 5 p. tab.
Descritores:HANSENIASE
LEPROSTATICOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
DAPSONA
DIIDROPTEROATO SINTASE
RESISTENCIA MICROBIANA A DROGAS
GENES BACTERIANOS
DADOS DE SEQUENCIA MOLECULAR
MUTAÇAO
Localização:BR191.1; 07334/s


  19 / 25 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14139
Autor:Cambau, Emmanuelle; Perani, Evelyne; Guillemin, Isabelle; Jamet, Pierre; Ji, Baohong
Título:Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae
..-
Fonte:s.l; s.n; 1997. 2 p. tab.
Descritores:AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
DAPSONA
RESISTENCIA A MULTIPLAS DROGAS
QUIMIOTERAPIA COMBINADA
LEPROSTATICOS
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
OFLOXACINA
RIFAMPINA
Limites:RELATO DE CASO
Localização:BR191.1; 07114/s


  20 / 25 HANSEN  
              first record previous record
seleciona
para imprimir
Id:13961
Autor:Mendis, Susirith; Somasiri, K. G; Chularatna, W
Título:Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients
..-
Fonte:s.l; s.n; 1993. 4 p. tab.
Descritores:CLOFAZIMINA
CLOFAZIMINA
DAPSONA
DAPSONA
QUIMIOTERAPIA COMBINADA
ELETROFISIOLOGIA
HANSENIASE
HANSENIASE
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
CONDUÇAO NERVOSA
NERVOS PERIFÉRICOS
NERVOS PERIFÉRICOS
TEMPO DE REAÇAO
RIFAMPINA
RIFAMPINA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
Localização:BR191.1; 06607/s



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information